Date | Price Target | Rating | Analyst |
---|---|---|---|
1/30/2024 | $68.00 → $38.00 | Buy → Neutral | BofA Securities |
12/12/2023 | $62.00 | Buy | Deutsche Bank |
4/24/2023 | $80.00 | Outperform | SVB Securities |
1/27/2023 | $94.00 | Overweight | Piper Sandler |
11/4/2022 | $52.00 → $55.00 | Outperform → Sector Perform | RBC Capital Mkts |
9/28/2022 | Neutral → Buy | BofA Securities | |
11/19/2021 | $77.00 | Market Outperform | JMP Securities |
9/30/2021 | $59.00 → $82.00 | Outperform | RBC Capital |
Chad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functions Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity at a large pharmaceutical company to lead a global product development division Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena's executive leadership team and will report to Gene Kin
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5; 1x1 investor meetings will be held Cantor Global Healthcare Conference on Tuesday, September 17; a fireside chat will be held at 1:55 PM ET A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live present
Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months of 2024; quarter-end cash and restricted cash position was $565.0 million Revised year-end cash guidance to be approximately $468 million in cash, cash equivalents and restricted cash, representing an increase of $63 million from prior guidance of $405 million Bristol Myers Squibb obtained the exclusive global license for PRX019 for $80 million, a potential treatment of neurodegenerative disease with an undisclosed target; Prothena to initiate a Phase 1 clinical trial by YE 2024 Partner Br
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
S-8 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
RBC Capital analyst Brian Abrahams reiterates Prothena Corp (NASDAQ:PRTA) with a Sector Perform and maintains $28 price target.
JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $85 to $83.
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
SC 13G - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
BofA Securities downgraded Prothena from Buy to Neutral and set a new price target of $38.00 from $68.00 previously
Deutsche Bank initiated coverage of Prothena with a rating of Buy and set a new price target of $62.00
SVB Securities initiated coverage of Prothena with a rating of Outperform and set a new price target of $80.00
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the pot
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of
Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million The company expects cash guidance for the full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash (midpoint) Advanced potential best-in-class Alzheimer's disease portfolio in 2023: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta
Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board's regular succession planning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221419945/en/Daniel G. Welch (Photo: Business Wire) Upon election by the shareholders at Prothena's Annual General Meeting later this year, the Board intends to appoint Mr. Welch a